I agree that this site is using cookies. You can find further informations here.
X
Odem-Davis, K.
53  results:
Search for persons X
?
1

Heterogeneity of CFTR modulator-induced sweat chloride conc..:

Zemanick, E.T. ; Emerman, I. ; McCreary, M....
Journal of Cystic Fibrosis.  , 2024
Link: https://doi.org/10.1016/..
 
?
2

WS15.01 Maternal and fetal outcomes in the era of CFTR modu..:

Taylor-Cousar, J.L. ; Emerman, I. ; Odem-Davis, K....
Journal of Cystic Fibrosis.  23 (2024)  - p. S27 , 2024
Link: https://doi.org/10.1016/..
 
?
3

104 Effect of acute systemic corticosteroids on clinical ou..:

McElvaney, O. ; Heltshe, S. ; Odem-Davis, K....
Journal of Cystic Fibrosis.  22 (2023)  - p. S55 , 2023
Link: https://doi.org/10.1016/..
 
?
4

Characterizing CFTR modulated sweat chloride response acros..:

Mayer-Hamblett, N ; Zemanick, ET ; Odem-Davis, K...
Journal of Cystic Fibrosis.  22 (2023)  1 - p. 79-88 , 2023
Link: https://doi.org/10.1016/..
 
?
5

P090 Treatment use among SIMPLIFY trial participants throug..:

Gifford, A.H. ; Odem-Davis, K. ; Kloster, M....
Journal of Cystic Fibrosis.  22 (2023)  - p. S91 , 2023
Link: https://doi.org/10.1016/..
 
?
6

Willingness of people with cystic fibrosis receiving elexac..:

VanDevanter, D.R. ; Zemanick, E.T. ; Konstan, M.W....
Journal of Cystic Fibrosis.  22 (2023)  4 - p. 652-655 , 2023
Link: https://doi.org/10.1016/..
 
?
7

P084 Willingness of people treated with elexacaftor/tezacaf..:

VanDevanter, D. ; Odem-Davis, K. ; Emerman, I....
Journal of Cystic Fibrosis.  22 (2023)  - p. S89 , 2023
Link: https://doi.org/10.1016/..
 
?
8

43 Cystic fibrosis transmembrane conductance regulator modu..:

Konstan, M. ; Mayer-Hamblett, N. ; Odem-Davis, K....
Journal of Cystic Fibrosis.  21 (2022)  - p. S26-S27 , 2022
Link: https://doi.org/10.1016/..
 
?
9

261 Concentrations of elexacaftor/tezacaftor/ivacaftor in t..:

Guimbellot, J. ; Natt, J. ; Ryan, K....
Journal of Cystic Fibrosis.  21 (2022)  - p. S154 , 2022
Link: https://doi.org/10.1016/..
 
?
10

606 Focused clinical trials of modulator response for rare ..:

Solomon, G. ; Suzuki, S. ; Hathorne, H....
Journal of Cystic Fibrosis.  21 (2022)  - p. S336 , 2022
Link: https://doi.org/10.1016/..
 
?
11

555: Clinical trial interest after establishment of modulat..:

Mayer-Hamblett, N. ; Clancy, J. ; Odem-Davis, K....
Journal of Cystic Fibrosis.  20 (2021)  - p. S262 , 2021
Link: https://doi.org/10.1016/..
 
?
12

A Simulation Study Evaluating Bio-Creep Risk in Serial Noni..:

Odem-Davis, K. ; Fleming, T. R.
Statistics in Biopharmaceutical Research.  7 (2015)  1 - p. 12-24 , 2015
Link: https://doi.org/10.1080/..
 
?
13

Variation in Patterns of Care in the United States for Clin..:

Beard, C.J. ; Jeldres, C. ; Odem-Davis, K....
International Journal of Radiation Oncology*Biology*Physics.  90 (2014)  1 - p. S469 , 2014
Link: https://doi.org/10.1016/..
 
?
14

Compartmentalized Cytomegalovirus Replication and Transmiss..:

Slyker, J. ; Farquhar, C. ; Atkinson, C....
Clinical Infectious Diseases.  58 (2013)  4 - p. 564-572 , 2013
Link: https://doi.org/10.1093/..
 
?
15

CHARACTERIZING CFTR MODULATED SWEAT CHLORIDE RESPONSE ACROS..:

Mayer-Hamblett, N ; Zemanick, ET ; Odem-Davis, K...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10103635/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
1-15